Munich, September 16, 2024 – Reactive Robotics is becoming a pioneer in AI- and robot-assisted mobilization in hospitals, geriatrics, and nursing care. Investors such as Dr. Doll, the TQ Group, Henrik Schunk, Stephan Huber, and the EIC Fund share this vision and are providing the MedTech company with an additional €5 million to support its growth. In 2023, the company had already been awarded €2.5 million in funding for its R&D activities by the European Innovation Council.

With this new funding, Reactive Robotics will continue to develop its globally unique AI-supported robotic assistance system, VEMOTION, designed for patients, caregivers, therapists, and medical professionals, while also advancing its national and international market launch.
Thanks to their assistive robotics, critically ill and intensive care patients have already received more than 5.000 mobilizations, which are critical for faster recovery. The system physically relieves caregivers and therapists when working with patients weighing up to 180 kg and, despite staff shortages, creates new opportunities with the “colleague VEMOTION.” By using the system, hospital management gains three key levers: relieving the burden on staff, supporting the implementation of the S3 guideline for positioning therapy and mobilization of critically ill patients in intensive care units, as well as a quick return on investment. In future, VEMOTION will offer practitioners more and more support based on relevant data as the number of cases increases.

“We are thrilled by the trust our investors have placed in us. This funding round is a significant step for Reactive Robotics and enables us to implement our vision of improved and efficient patient care and staff relief,” says Brigitte Schrätzenstaller, Managing Director of Reactive Robotics GmbH. Maximilian Große-Dunker, Managing Director and COO, adds: “With additional resources, we will continue to pursue our data strategy and internationalization consistently.”

“We firmly believe in Reactive Robotics’ potential to revolutionize the healthcare industry. The combination of innovative technology and a dedicated team makes the company a promising player in the field of medical robotics,” commented Dr. Theo Doll, one of the early-stage investors.